Dyne Therapeutics (NASDAQ:DYN) Releases Earnings Results, Misses Expectations By $0.34 EPS

Dyne Therapeutics (NASDAQ:DYN) posted its quarterly earnings data on Wednesday. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.34), FiscalAI reports.

Dyne Therapeutics Stock Performance

Shares of DYN stock traded down $0.80 during trading on Wednesday, hitting $25.10. The company’s stock had a trading volume of 2,104,646 shares, compared to its average volume of 2,118,053. Dyne Therapeutics has a 52 week low of $9.32 and a 52 week high of $26.26. The company has a market cap of $4.68 billion, a PE ratio of -7.80 and a beta of 1.06. The business has a fifty day moving average of $20.76 and a 200-day moving average of $18.72. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Sanford C. Bernstein increased their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Cantor Fitzgerald assumed coverage on Dyne Therapeutics in a research note on Thursday, July 23rd. They issued an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. TD Cowen started coverage on Dyne Therapeutics in a research report on Friday, June 26th. They set a “buy” rating on the stock. Finally, Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 480,240 shares of Dyne Therapeutics stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $22.79, for a total value of $10,944,669.60. Following the sale, the director owned 875,912 shares of the company’s stock, valued at approximately $19,962,034.48. The trade was a 35.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have bought 9,000 shares of company stock worth $156,800 and have sold 1,665,542 shares worth $36,321,576. Insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently modified their holdings of the stock. Aster Capital Management DIFC Ltd bought a new stake in shares of Dyne Therapeutics in the 4th quarter worth approximately $84,000. Steward Partners Investment Advisory LLC increased its position in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after buying an additional 7,697 shares during the period. Prudential Financial Inc. bought a new stake in shares of Dyne Therapeutics in the second quarter valued at $111,000. Finally, Creative Planning lifted its position in shares of Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after buying an additional 2,797 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.